Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov 1;124(18):e466-8.
doi: 10.1161/CIRCULATIONAHA.111.067918.

Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling

Jane A Leopold  1
Affiliations
Review

Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling

Jane A Leopold. Circulation. .
No abstract available

PubMed Disclaimer

References

    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–717. - PubMed
    1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321. - PubMed
    1. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21. - PubMed
    1. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2:370–376. - PubMed
    1. Maron BA, Leopold JA. Aldosterone receptor antagonists: Effective but often forgotten. Circulation. 2010;121:934–939. - PMC - PubMed

Publication types

MeSH terms